Safety and Basic Knowledge

Participant safety and wellbeing must take precedence over scientific objectives at all times. Therapists must communicate and operationalize this priority throughout screening, treatment, and follow-up.

4 care stages · 4 guidelines · 0 courses · 0 providers

The provided source text is only a ClinicalTrials.gov interface/header snippet and does not contain study intervention procedures, therapist qualifications, facilitator responsibilities, safety monitoring procedures, or ethical guidance specific to clinical practice.

2 care stages · 3 guidelines · 0 courses · 0 providers

Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.

8 care stages · 2 guidelines · 5 courses · 5 providers

Facilitators are expected to have substantial prior experience supporting altered states of consciousness. This experience supports containment, trust, and skilled response to unusual perceptual and emotional phenomena.

2 care stages · 2 guidelines · 0 courses · 0 providers

Understand the characteristic acute experiential domains elicited by ayahuasca. This includes perceptual, somatic, cognitive, affective, mystical, and temporal-spatial alterations.

3 care stages · 2 guidelines · 0 courses · 0 providers

Therapists must be specifically trained in psilocybin-assisted psychotherapy and in the study’s manualized procedures. Competence includes familiarity with the therapeutic model and difficult-state management guidance.

4 care stages · 2 guidelines · 0 courses · 0 providers

Ability to acknowledge when the source does not contain therapist or facilitator competency information. The extractor should not overstate what can be supported by the text.

1 care stage · 1 guidelines · 0 courses · 0 providers

Financial arrangements should be communicated clearly and handled transparently. Facilitators should avoid ambiguity around fees, deposits, scholarships, and contribution models.

1 care stage · 1 guidelines · 0 courses · 0 providers

Track onset, duration, and phases of ibogaine effects as part of clinical monitoring. The manual describes multiple stages of effect and expects the provider to observe them carefully.

3 care stages · 1 guidelines · 0 courses · 0 providers

The facilitator should understand how posture affects the experience and support safer, freer bodily expression. Positioning may include lying down, sitting, standing, or allowing spontaneous movement as appropriate.

1 care stage · 1 guidelines · 0 courses · 0 providers

Assistant facilitators require practical clinical experience in a licensed healthcare setting. Their role supports safety, containment, and session logistics rather than independent psychotherapy practice.

2 care stages · 1 guidelines · 0 courses · 0 providers

The protocol implies that facilitators should have specific psychiatric, psychotherapeutic, or psycholytic therapy training relevant to altered-state treatment. Specialized experience supports safe and effective delivery of LSD-assisted psychotherapy.

1 care stage · 1 guidelines · 0 courses · 0 providers

Participants must be continuously monitored to prevent avoidable hazards. The guide explicitly states that participants should never be left alone.

1 care stage · 1 guidelines · 0 courses · 0 providers

Implement infection-prevention procedures during in-person study and dosing visits. Facilitators must screen participants, use PPE, maintain distancing when feasible, and adapt procedures based on test results or symptoms.

3 care stages · 1 guidelines · 0 courses · 0 providers

Plan ibogaine dosing based on patient status, formulation, prior opioid exposure, and therapeutic goals. The manual presents both single-dose and multi-dose approaches and stresses patient-specific judgment.

1 care stage · 1 guidelines · 0 courses · 0 providers

A clear emergency plan is required before the session begins. The whole team must understand what to do in various scenarios.

1 care stage · 1 guidelines · 0 courses · 0 providers

The handbook explicitly states that therapists should understand the drug effects through personal experience, because direct familiarity improves empathy, guidance, and integration work. Staff who will interact with patients are ideally similarly trained.

1 care stage · 1 guidelines · 0 courses · 0 providers

Providers must maintain hydration and avoid electrolyte depletion because dehydration and electrolyte abnormalities increase cardiac risk. Hydration is to be monitored before, during, and after treatment.

1 care stage · 1 guidelines · 0 courses · 0 providers

The therapist/facilitator should know the expected onset, peak, and persistence of effects to guide monitoring and interpretation. The source reports acute effects with follow-up improvements lasting days.

4 care stages · 1 guidelines · 0 courses · 0 providers

Order, review, and interpret core laboratory studies relevant to ibogaine safety and metabolism. Competence includes recognizing abnormal values that increase risk or signal exclusion from treatment.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators are expected to monitor for signs of misuse, diversion, dependence, or other abuse-related phenomena even though the medication is administered only on-site. They must also recognize protocol violations or dropout patterns that may signal abuse liability concerns.

3 care stages · 1 guidelines · 0 courses · 0 providers

Maintains awareness that any clinical trial context may involve participant risk and requires appropriate safeguards. Even minimal source text implies the need for cautious, non-assumptive practice.

1 care stage · 1 guidelines · 0 courses · 0 providers

Verify the formulation and potency of the ibogaine product before administration. The manual warns that confusion between HCl, extract, and root bark can cause underdosing or fatal overdosing.

2 care stages · 1 guidelines · 0 courses · 0 providers

Identify and document possible post-dose reactivation or flashback-like experiences. The therapist must capture timing, context, emotional valence, and functional impact of these events.

3 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators should be aware that outcome variability may reflect both drug effects and psychological support effects. The source notes that fidelity was not assessed, underscoring the need for humility and careful practice.

1 care stage · 1 guidelines · 0 courses · 0 providers

If physical intervention is needed, it must be done carefully to reduce risk such as choking or aspiration. The facilitator should understand safer alternatives and avoid dangerous techniques.

1 care stage · 1 guidelines · 0 courses · 0 providers

Maintain physical, emotional, and relational safety as the primary guiding principle throughout IMAP. Therapists continuously monitor risk, reinforce boundaries, and intervene more directly when safety is compromised.

1 care stage · 1 guidelines · 0 courses · 0 providers

Decide when sedation is appropriate and select agents that have been used safely in the manual’s reports. Sedation is presented as optional and patient-specific, not routine.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators should understand how to work in one-on-one, group, and advanced simultaneous group formats. They must clearly explain the context, method, and risks of their chosen format.

1 care stage · 1 guidelines · 0 courses · 0 providers

The facilitator influences the participant’s mindset through tone, language, responsiveness, and overall presence. They should intentionally support a conducive mental set from first contact through post-session care.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators should know when silence is best and when brief dialogue can help orient or reassure. Words should be used sparingly, precisely, and with awareness of their power.

1 care stage · 1 guidelines · 0 courses · 0 providers

The protocol specifies that therapists require relevant professional qualifications and dedicated training in both the CBT manual and ketamine-assisted psychotherapy adaptations. Competent delivery depends on staying within scope and using protocol-specific training.

1 care stage · 1 guidelines · 0 courses · 0 providers

Knowledge that KAP may be delivered without intravenous access and that non-IV office-based use is part of the described practice model. This reflects a shift from IV-only psychiatric use to broader administration approaches.

2 care stages · 1 guidelines · 0 courses · 0 providers

Cluster covering 7 related competencies including: Psychedelic therapy foundation, Psychedelic therapy foundations, Psychedelic practice fundamentals.

4 care stages · 0 guidelines · 6 courses · 5 providers

Teaches the neurobiological basis of psychedelic and non-ordinary states, including default mode, salience, fear, and related brain-network models. The competency links altered-state phenomenology with therapeutic mechanisms and clinical implications.

5 care stages · 0 guidelines · 4 courses · 4 providers

The course teaches learners to distinguish between classic psychedelics and emerging therapies within therapeutic applications. This is a foundational comparative literacy competency rather than a protocol-specific skill.

6 care stages · 0 guidelines · 1 courses · 1 providers

The course presents scientific theories about how psychedelics may exert therapeutic effects. Learners are introduced to mechanisms such as psychological flexibility and interpersonal engagement.

1 care stage · 0 guidelines · 1 courses · 1 providers

The course explicitly states that facilitators are guided in safety, ethics, and responsibility. Learners are expected to recognize and manage the unique risks of working with altered states.

6 care stages · 0 guidelines · 1 courses · 1 providers

The course is positioned as a preparedness-oriented training with self-directed preparation plus live facilitated learning. Learners are expected to internalize a framework for managing challenging or crisis moments with confidence and care.

2 care stages · 0 guidelines · 1 courses · 1 providers

Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.

7 care stages · 29 guidelines · 3 courses · 3 providers

Cluster covering 9 related competencies including: Psilocybin facilitation, Psilocybin session support, Psilocybin facilitation basics.

8 care stages · 14 guidelines · 6 courses · 5 providers

Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.

6 care stages · 13 guidelines · 0 courses · 0 providers

The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.

7 care stages · 11 guidelines · 0 courses · 0 providers

Teaches practices that support preparation and therapeutic presence, including mindfulness, intention-setting, body-aware attention, environmental preparation, mindset awareness, and regulation through somatic presence.

7 care stages · 9 guidelines · 7 courses · 6 providers

Teaches how to instruct participants on post-dose and study-period restrictions that reduce risk from impaired judgment, unsafe activity, prohibited substances, or behaviors that could confound study outcomes.

6 care stages · 8 guidelines · 0 courses · 0 providers

Cluster covering 2 related competencies including: Psychedelic-assisted therapy facilitation, Group facilitation in a psychedelic setting.

6 care stages · 8 guidelines · 0 courses · 0 providers

Teaches providers to create and maintain a psychologically and physically safe therapeutic setting through clear structure, preparation, boundaries, attunement, environmental design, and ongoing attention to participant safety.

5 care stages · 6 guidelines · 2 courses · 2 providers

Provide a calm and supportive environment during treatment to reduce distress and support tolerance of the experience. The case report notes food, rest, and a quiet place as part of care.

6 care stages · 6 guidelines · 0 courses · 0 providers

Cluster covering 4 related competencies including: Psychedelic therapy workflow, Psilocybin psychotherapy framework, Psilocybin-assisted psychotherapy framework.

8 care stages · 5 guidelines · 4 courses · 2 providers

Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.

8 care stages · 5 guidelines · 2 courses · 2 providers

Know the medical and psychiatric exclusions that protect participants from foreseeable harm. Facilitators must recognize conditions that make MDMA-assisted psychotherapy unsafe or inappropriate.

4 care stages · 5 guidelines · 0 courses · 0 providers

Teaches sustainable self-care practices for clinicians and facilitators working in emotionally intense settings. The competency supports emotional resilience, ethical boundaries, reflective practice, and burnout prevention.

6 care stages · 4 guidelines · 3 courses · 3 providers

Understands that MDMA is a Schedule 1 investigational product and must be stored, dispensed, and accounted for under regulatory control. Supports compliant handling during the session.

4 care stages · 4 guidelines · 0 courses · 0 providers

Competent facilitation requires practical knowledge of dosage ranges, initial dosing, boosters, formulation handling, and administration errors. The handbook stresses both clinical judgment and meticulous procedural care.

3 care stages · 4 guidelines · 0 courses · 0 providers

The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.

5 care stages · 4 guidelines · 0 courses · 0 providers

Teaches clear communication of behavioral requirements before dosing sessions so conditions are standardized and preventable risks are reduced. Staff confirm that participants understand and follow pre-session instructions.

4 care stages · 4 guidelines · 0 courses · 0 providers

Therapists/facilitators must know the psychiatric and medical conditions that make KPT unsafe or inappropriate. Safe practice depends on excluding high-risk individuals.

3 care stages · 4 guidelines · 0 courses · 0 providers

The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.

6 care stages · 3 guidelines · 1 courses · 1 providers

The page points to checklists and a guide to basic medical emergencies, indicating that learners should be able to monitor safety and recognize urgent issues. The overall training context also stresses keeping both client and practitioner safe.

6 care stages · 3 guidelines · 1 courses · 1 providers

Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.

4 care stages · 3 guidelines · 0 courses · 0 providers

Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.

4 care stages · 3 guidelines · 0 courses · 0 providers

Therapists must understand MDMA’s expected subjective, interpersonal, and physiological effects and prepare participants accordingly. This knowledge supports normalization, reassurance, and effective use of the medicine within therapy.

4 care stages · 3 guidelines · 0 courses · 0 providers

Facilitators need practical skills in preparing participants emotionally for ketamine administration and reducing distress. The protocol highlights relaxation, breathing, and grounding strategies to reduce anxiety or discomfort associated with the drug experience.

3 care stages · 3 guidelines · 0 courses · 0 providers

Learners are explicitly offered Basic Life Support training, indicating emergency readiness and medical safety preparation. The page notes DORA-required status, signaling regulatory safety relevance.

4 care stages · 2 guidelines · 1 courses · 1 providers

The curriculum explicitly includes therapist self-regulation as a therapeutic skill. This suggests learners are expected to maintain steadiness and presence while supporting clients in altered states.

3 care stages · 2 guidelines · 1 courses · 1 providers

The therapist must exercise clinical judgment about who may benefit, who may have difficulty surrendering defenses, and where evidence is limited. The handbook emphasizes uncertainty, need for research, and cautious selection based on insecurity, rigidity, suspicion, diagnosis, and treatment goals.

3 care stages · 2 guidelines · 0 courses · 0 providers

Use brief mindfulness practices and grounding strategies to stabilize attention and reduce distress before and during the session. These techniques help the patient reconnect to present-moment awareness and bodily sensation.

3 care stages · 2 guidelines · 0 courses · 0 providers

Recognize and respond to gastrointestinal adverse effects that may occur frequently with higher doses. Manage emesis to reduce aspiration risk, dehydration, and treatment disruption.

3 care stages · 2 guidelines · 0 courses · 0 providers

Teaches how to interpret the psychedelic clinical evidence base, compare strength of evidence across indications, understand mechanism theories, and critically appraise research claims. The competency supports evidence-informed practice rather than relying on general field narratives.

7 care stages · 1 guidelines · 11 courses · 8 providers

Cluster covering 2 related competencies including: Trauma-informed care, Trauma-informed psychedelic care.

8 care stages · 1 guidelines · 4 courses · 4 providers

Cluster covering 2 related competencies including: Trauma-informed practice, Trauma-informed clinical practice.

7 care stages · 1 guidelines · 2 courses · 1 providers

Before administration, facilitators should assess readiness and factors that could increase the chance of a difficult session. The source highlights that preoccupation, rigidity, low trust, and poor support can worsen experiences.

4 care stages · 1 guidelines · 0 courses · 0 providers

The study specifically reports no QT prolongation, indicating that cardiac safety was an important monitoring domain. Facilitators must be aware of relevant safety surveillance and the need to identify concerning effects.

1 care stage · 1 guidelines · 0 courses · 0 providers

The conclusion emphasizes that findings apply to a selected group of patients, implying the importance of appropriate patient selection and caution in generalization when facilitating treatment.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators must work in a structured team environment with a separate study monitor and backup facilitators. They need to respond rapidly when additional 1:1 support is required and accept direction from the lead facilitator and PI.

1 care stage · 1 guidelines · 0 courses · 0 providers

Identifies and reports device deficiencies and product quality complaints related to the nasal spray device or product packaging. Ensures immediate escalation when malfunctions or labeling issues occur.

1 care stage · 1 guidelines · 0 courses · 0 providers

Responsibility to use LSD only within an ethically justified, clinically supervised framework. The source does not specify safeguards, but the therapeutic use of a potent psychoactive substance requires careful ethical oversight.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists should prepare participants by describing common psychological and physiological effects of MDMA and emphasizing variability of response.

1 care stage · 1 guidelines · 0 courses · 0 providers

Can evaluate whether ibogaine is being considered in the context of a highly selected clinical case, based on the source’s description of a severe, treatment-refractory patient. This includes understanding the limited evidence base and the need for careful patient selection.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understands the implications of PET, MRI, blood sampling, and TMS-EEG procedures for participant comfort and safety. While not necessarily performing these procedures, the therapist/facilitator should know their risks and scheduling constraints.

2 care stages · 1 guidelines · 0 courses · 0 providers

Clearly explain the investigational nature of ibogaine treatment and its known serious risks before treatment begins. Ethical practice requires that patients understand both uncertain benefits and significant safety concerns.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understands the therapeutic role of ayahuasca as a psychoactive plant brew used ritually in traditional Amazonian medicine. Knowledge of the cultural and medicinal context is necessary to support safe and appropriate facilitation.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand the basic rationale for ibogaine’s proposed effects in substance use disorders. This includes its reported ability to ease withdrawal, reduce craving, and act through multiple neurotransmitter systems.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need to understand the full treatment sequence and how each phase contributes to safety and treatment delivery. The intervention depends on correct sequencing and timing.

6 care stages · 1 guidelines · 0 courses · 0 providers

Therapists are expected to understand common features, characteristic reaction types, and sequential stages of the experience, because guidance differs by phase. The handbook repeatedly links competency to recognizing where the subject is in the process.

1 care stage · 1 guidelines · 0 courses · 0 providers

Clinicians need working knowledge of the potential risks and benefits of MDMA-assisted therapy as the research is designed to explore both. This knowledge supports informed consent, clinical judgment, and participant monitoring.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitator must know the conceptual basis and components of MORE. The protocol links mindfulness, savoring, and reappraisal to changes in craving and reward processing.

1 care stage · 1 guidelines · 0 courses · 0 providers

Able to deliver or support an 8-week MBSR curriculum for clinical populations. This requires knowledge of mindfulness practices and the ability to adapt them to frontline healthcare providers experiencing depression and burnout.

1 care stage · 1 guidelines · 0 courses · 0 providers

Monitor for cerebellar toxicity and gait disturbance because severe transient ataxia was observed in all patients in the study. The facilitator must be able to detect impaired coordination and prevent falls or injury.

2 care stages · 1 guidelines · 0 courses · 0 providers

A study physician with psychiatric and cardiovascular emergency expertise must be available during dosing. This reflects a requirement for advanced emergency readiness and clinical judgment.

3 care stages · 1 guidelines · 0 courses · 0 providers

Recognize that placebo response can be substantial in depression trials and that supportive care may amplify expectancy effects. Facilitators should avoid unintentionally inflating suggestibility beyond the protocol.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists should have standard training in psychotherapy for anxiety associated with medical illness and would benefit substantially from personal familiarity with non-ordinary states of consciousness. Such understanding improves empathy, confidence, and process navigation.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators need knowledge of a structured curriculum informed by psychology and resilience science. They must be able to teach and reinforce core resilience factors and translate them into experiential group practices.

1 care stage · 1 guidelines · 0 courses · 0 providers

Because participants may be more suggestible during psychedelic sessions, therapists must actively protect against manipulation and unsafe influence. This requires vigilance and careful conduct.

2 care stages · 1 guidelines · 0 courses · 0 providers

Can explain common, psychological, and severe risks of KAP in understandable terms. Sets realistic expectations that outcomes may vary and are not guaranteed.

2 care stages · 1 guidelines · 0 courses · 0 providers

The facilitator should understand the administration context for the intervention. The source highlights inhalation as the studied route and its rapid onset.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need working knowledge of administration routes because onset, duration, intensity, and tolerability vary substantially. This informs preparation, monitoring, and participant education.

3 care stages · 1 guidelines · 0 courses · 0 providers

Know that ayahuasca composition can vary and that chemical characterization matters. Facilitators or clinical teams should understand the potency and stability of the administered brew.

2 care stages · 1 guidelines · 0 courses · 0 providers

Use supervision, debriefing, and personal reflection to manage the intensity and complexity of IMAP work. Therapists need support to stay effective and ethically grounded.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists should be able to help patients face anxiety, fear of death, hopelessness, and suffering associated with life-threatening illness. The treatment context explicitly targets existential distress and uses LSD sessions to engage these themes.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists must be comfortable with powerful affect and able to support its expression without becoming reactive or controlling. Their role includes normalizing, containing, and encouraging tears, sounds, movement, and other forms of emotional release.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists should understand multiplicity of the psyche as a normal phenomenon that may become more apparent in trauma treatment and altered states. They must respond with curiosity and support rather than pathologizing parts, selves, or dissociative phenomena unless clinically necessary.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists must understand that parts, selves, subpersonalities, or dissociative-like multiplicity can emerge normally, especially in trauma. They should not pathologize these experiences and should help use them therapeutically.

1 care stage · 1 guidelines · 0 courses · 0 providers

The article indicates that a structured, supportive context is associated with more positive acute and enduring effects and fewer challenging experiences. Facilitators should actively design the session context around safety and support.

2 care stages · 1 guidelines · 0 courses · 0 providers

Operate only within the bounds of formal training, supervision, and site authorization. The protocol expects specialized training for facilitators, raters, and all staff interacting with participants or data.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators must coordinate appropriate overnight support personnel and ensure they are trained for the role. Attention to participant comfort and boundaries is built into staffing decisions.

1 care stage · 1 guidelines · 0 courses · 0 providers

Teaches practitioners to read and understand clinical protocols, treatment manuals, and evidence-based psychedelic care procedures. The focus is knowing how protocol requirements shape preparation, dosing, integration, documentation, and safety responsibilities.

5 care stages · 0 guidelines · 2 courses · 2 providers

Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.

6 care stages · 0 guidelines · 2 courses · 1 providers

The course repeatedly emphasizes ethical considerations, safety, and integrity in practice. Learners are expected to develop a grounded professional stance that respects legal boundaries and participant welfare.

3 care stages · 0 guidelines · 1 courses · 1 providers

The course explicitly teaches techniques for working with patients in altered states, including grounding, breathwork, and mindfulness. These are presented as tools for supporting expanded and ordinary states of consciousness.

2 care stages · 0 guidelines · 1 courses · 1 providers

A defining feature of the training is hands-on experiential practice in both non-substance and substance-based modalities under supervision. Learners practice patient and therapist roles, facilitating and undergoing sessions in a structured learning context.

5 care stages · 0 guidelines · 1 courses · 1 providers

The program states that the virtual training has been streamlined so students feel safe and supported no matter what arises. This signals competency in maintaining safety in online psychedelic support contexts.

3 care stages · 0 guidelines · 0 courses · 1 providers

Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.

8 care stages · 45 guidelines · 27 courses · 18 providers